DANZITEN vs EVEROLIMUS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 14, 2026·How we rate

Possible drug interaction. DANZITEN and EVEROLIMUS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	DANZITEN	EVEROLIMUS
Rating	70/100	70/100
Pharmacy pays	—	~$234.69 /30
Type	RX	RX
Active ingredient	NILOTINIB TARTRATE	EVEROLIMUS
Manufacturer	Azurity	Biocon Pharma
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	Boxed warning
Half-life	—	about 30 hours (mean terminal elimination half-life)
Treats	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors	—

danziten everolimus

Rating

70/100

Pharmacy pays

—

~$234.69 /30

Type

Active ingredient

NILOTINIB TARTRATE

EVEROLIMUS

Manufacturer

Azurity

Biocon Pharma

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

Half-life

—

about 30 hours (mean terminal elimination half-life)

Treats

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

—

Frequently asked questions

Which is better-rated, Danziten or Everolimus?

Danziten and Everolimus are tied at 3.5 out of 5 by our independent rating.

What is the difference between Danziten and Everolimus?

Danziten contains Nilotinib Tartrate, while Everolimus contains Everolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.